Skip to main content
    B

    BridgeBio Pharma Inc (BBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $77.36
    -0.94 (-1.20%)

    Market Cap: $15.25B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BridgeBio Pharma Inc (BBIO) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to BridgeBio Pharma are Bio-Techne (TECH), Krystal Biotech (KRYS) and TG Therapeutics (TGTX). By market cap, BridgeBio Pharma ranks 3rd of the 13 companies on this page; Roivant Sciences (ROIV) is the largest at $28.64B. The median P/E of the 6 companies with a P/E is 33.7x.

    Peer Comparison

    BBIO's ROIC of -33.0% is below the peer median of 9.3%, and its revenue growth of 192.6% is above the median of 29.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    BridgeBio Pharma (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    Bio-Techne Corp (TECH)$11.44B39.6x9.3x14.0%7.7%4.6%0.44%
    Krystal Biotech Inc (KRYS)$9.05B40.4x18.8x47.9%N/A30.2%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Madrigal Pharmaceuticals Inc (MDGL)$9.93BN/A8.7x-10.9%-12.7%50.1%0.00%
    Exelixis Inc (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Summit Therapeutics PLC (SMMT)$11.32BN/AN/A0.0%N/A-100.0%0.00%
    Halozyme Therapeutics Inc (HALO)$11.43B17.8x6.1x26.9%15.8%39.2%0.00%
    Spyre Therapeutics Inc. (SYRE)$9.88BN/AN/A0.0%N/A0.0%0.00%
    Roivant Sciences Ltd (ROIV)$28.64BN/A679.3x0.0%N/A2136.0%0.00%
    Twist Bioscience Corp (TWST)$7.40BN/A14.3x-28.3%N/A27.9%0.00%
    Apogee Therapeutics, Inc. Common Stock (APGE)$10.22BN/AN/A0.0%N/A0.0%0.00%
    Peer median$10.08B33.7x11.1x5.9%9.3%29.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to BridgeBio Pharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Bio-Techne Corp (TECH)
    Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments...
    TECH competitors
    Krystal Biotech Inc (KRYS)
    Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United...
    KRYS competitors
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Madrigal Pharmaceuticals Inc (MDGL)
    Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates...
    MDGL competitors
    Exelixis Inc (EXEL)
    Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development...
    EXEL competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Summit Therapeutics PLC (SMMT)
    Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America...
    SMMT competitors
    Halozyme Therapeutics Inc (HALO)
    Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
    HALO competitors
    Spyre Therapeutics Inc. (SYRE)
    Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by...
    SYRE competitors
    Roivant Sciences Ltd (ROIV)
    Roivant Sciences Ltd (ROIV) is a transformative biopharmaceutical company focused on advancing drug development and commercialization through a distinctive...
    ROIV competitors
    Twist Bioscience Corp (TWST)
    Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products.
    TWST competitors
    Apogee Therapeutics, Inc. Common Stock (APGE)
    Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)...

    Frequently Asked Questions About BBIO

    Who are BridgeBio Pharma's main competitors?

    The companies most similar to BridgeBio Pharma include Bio-Techne (TECH), Krystal Biotech (KRYS), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL) and Exelixis (EXEL), listed from the closest match.

    Who is BridgeBio Pharma's biggest competitor?

    Roivant Sciences (ROIV) is the largest of the similar companies at $28.64B; Bio-Techne (TECH) is the closest match by business profile, size, sector and industry.

    How does BBIO stock compare with its competitors?

    BBIO's P/S is 16.0x against a peer median of 11.1x; its net margin is -59.8% against a peer median of 5.9%.

    Which of BridgeBio Pharma's competitors pays a higher dividend?

    BridgeBio Pharma pays no dividend. Bio-Techne (TECH) has a higher forward dividend yield; Bio-Techne (TECH) has the highest at 0.44%.

    Is BridgeBio Pharma bigger than its competitors?

    No. BridgeBio Pharma is 3rd by market cap among the 13 companies on this page; the largest is Roivant Sciences (ROIV) at $28.64B.